New Partnership Aims to Transform Cancer Treatment in Asia

Introduction to the Strategic Partnership

EnGeneIC, a biopharmaceutical company at the forefront of cancer treatment research, has recently announced a strategic partnership with the Singapore Institute of Advanced Medicine Holdings (SAM) and Singapore Medical Incorporation (SMI). This collaboration promises to bring substantial funding, allowing EnGeneIC to advance its clinical trial programs in Australia and the USA, as well as expedite the development and commercialization of its unique cancer treatment technology, the EnGeneIC Dream Vector (EDVTM).

What is the EnGeneIC Dream Vector (EDVTM)?

The EDVTM technology represents a breakthrough in cancer therapy. It utilizes targeted nanocells to deliver potent chemotherapeutic agents directly to cancer cells, minimizing toxicity and maximizing effectiveness. This innovative approach aims to overcome drug resistance in tumors and stimulates the patient's immune system to mount a strong anti-tumor response. The technology is currently in Phase IIa clinical trials for various aggressive and low-survival cancers.

Significance of the Partnership for Asia

The exclusive partnership with SAM grants the institute rights to sell EDV therapeutics across Asia. This commercial deal ensures that the majority of net profits from these sales will go to EnGeneIC. Additionally, SAM and EnGeneIC will collaborate on the development of EDV-based theranostics, which integrate diagnostic and therapeutic capabilities into a single platform for more precise and personalized cancer treatment.

Role of Crescendas Group in the Partnership

Singapore-based Crescendas Group, a key player in the partnership, will provide the necessary funds for the capital expenditure required to complete the next phase of clinical trials, aiming for FDA approval in the USA. Crescendas operates in multiple countries, including Singapore, Malaysia, China, and the Maldives, under the leadership of Mr. Lawrence Leow, a prominent businessman and former member of the Singapore parliament.

Statements from Key Leaders

Dr. Jennifer MacDiarmid, Joint CEO of EnGeneIC, expressed excitement about the partnership, emphasizing that it marks a significant expansion of their efforts into Asia. She highlighted that the collaboration would facilitate cGMP-manufacturing capabilities and clinical trials, making EDV technology accessible to a broader patient population.

Dr. Shih Kien Djeng, Chairman and CEO of SAM, shared his enthusiasm, stating that the partnership aligns with SAM's mission to advance medical innovation and improve patient outcomes. He believes that combining their strengths with EnGeneIC will help deliver revolutionary cancer treatments, offering new hope to patients across the region.

About EnGeneIC

EnGeneIC is dedicated to advancing its EDV® technology, a platform designed for oncology and infectious disease applications. By specifically targeting cancer cells with minimal toxicity, the EDV nanocell drug conjugate platform can deliver a range of therapeutic payloads, including drugs and genetic material, leading to more effective and personalized cancer treatments.

About Singapore Institute of Advanced Medicine Holdings

SAM is a leading healthcare service provider in Singapore, known for utilizing advanced technology for early diagnosis and treatment of various diseases, including cancer. SAM's services encompass Nuclear Medicine, Theranostics, Proton Therapy, and Radiation Therapy, and the institute has numerous strategic collaborations with both public and private entities for research and clinical work.

Expected Impact on Cancer Treatment

The partnership between EnGeneIC and SAM is expected to bring significant advancements in cancer treatment in Asia. By combining EnGeneIC's technological prowess with SAM's clinical infrastructure, the collaboration aims to revolutionize the way cancer is diagnosed and treated, providing more personalized and effective care for patients.

Conclusion

This strategic partnership represents a major step forward in the fight against cancer. With new funding and collaborative efforts, EnGeneIC's EDV technology has the potential to offer groundbreaking treatment options, improve patient outcomes, and ultimately transform cancer care across Asia.